Dryocrassin ABBA

本公司产品仅用于科研实验，不得用于人体或动物的临床与诊断

Dryocrassin ABBA (Dryocrassin) 是一种从 Dryopteris crassirhizoma 中提取的黄酮类天然产物，具有抗病毒和抗菌活性。 Dryocrassin ABBA 对 H5N1 禽流感病毒具有抗病毒活性。

Dryocrassin ABBA (Dryocrassin) is a flavonoid natural product derived from Dryopteris crassirhizoma, with antiviral and antibacterial activities. Dryocrassin ABBA exhibits antiviral activity against H5N1 avian influenza virus. Dryocrassin ABBA inhibits the coagulase activity of Staphylococcus aureus vWbp. Dryocrassin ABBA suppresses immunostimulatory function of dendritic cells and prolongs skin allograft survival.

Dryocrassin ABBA (Dryocrassin) inhibits the activity of S. aureus SrtA (sortase A) with an IC50 of 24.17 μM.

Dryocrassin ABBA (Dryocrassin) (0-33 mg/kg; i.g.; daily, 7 days from day 2 to day 8) exerts a significant dose-dependent antiviral effect in mice.Dryocrassin ABBA (100 mg/kg; s.c.; every 12 h for 96 h) can reduce infection and prevent mice from contracting S. aureus pneumonia. Animal Model:SPF BALB/C female mice inoculated intra-nasally with 104.5ELD50 H5N1 viruses in 100 μl salineDosage:33, 18, and 12.5 mg/kg Administration:Oral gavage, daily, 7 days from day 2 to day 8 Result:Significantly reduced mortality, prolonged survival rate, and improved survival time throughout the infection period. Increased body weight and reduced lung lesions and virus loads. Significantly increased MCP-1 and IL-10 while significantly decreased IL-12, IL-6, IFN-γ and TNF-α.Animal Model:Eight-week-old C57BL/6J mice infected with 30 μL of S. aureus Newman (2 × 108 CFU/10 μL) by intranasal administrationDosage:100 mg/kg Administration:Subcutaneous injection, every 12 h for 96 h Result:Resulted a significant increase in survival.

——

Microbiology/Virology

Influenza Virus

——

——

——

12777-70-7

820.83

C??H??O??

>98% (HPLC)

In Vitro:?DMSO : 16.67 mg/mL (20.31 mM)

OC1=C(C(O)=C(C(CCC)=O)C(O)=C1CC(C(C(C(C)=O)=C(O)C2(C)C)=O)=C2O)CC(C(O)=C(C(CCC)=O)C(O)=C3CC(C(C(C(C)=O)=C(O)C4(C)C)=O)=C4O)=C3O

——

(-20℃)

With Ice Pack

≥ 2 years